Progress and problems with the use of viral vectors for gene therapy
The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
Gene therapy has a history of controversy. Encouraging results are starting to emerge from the clinic, but questions are still being asked about the safety of this new molecular medicine. With the development of a leukaemia-like syndrome in two of the small number of patients that have been cured of a disease by gene therapy, it is timely to contemplate how far this technology has come, and how far it still has to go.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In all cases of leukemia, the SCID X-1 correcting gene had inserted into the patient genome within or near tumor-promoting genes and caused transcriptional activation (Check, 2002; Kaiser, 2003; Thomas et al., 2003).”
From Delivering CRISPR: a review of the challenges and approaches (2018) · cites this paper as Thomas et al., 2003
Citations
Cites
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167 · cited 1×
“Recent evidence from a number of separate studies has challenged our perceptions about the risks of using integrating retrovirus vectors for certain types of gene therap”
BackgroundA serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867 · cited 1×
“Recent evidence from a number of separate studies has challenged our perceptions about the risks of using integrating retrovirus vectors for certain types of gene therap”
BackgroundHIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,760
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 1×
“AAV vector genomes flanked by AAV2 inverted terminal repeats (ITRs) have also been successfully cross-packaged in the capsids of alternative serotypes, creating a portfolio of pseudotypes with different specificitie”
BackgroundRubinson, D. A., Dillon, C. P., Kwiatkowski, A. V., Sievers, C., Yang, L., Kopinja, J., Rooney, D. L., Zhang, M., Ihrig, M. M., McManus, M. T., et al. (2003) · Nature Genetics · doi:10.1038/ng1117 · Cited by 1,501
Naldini, L., Blömer, U., Gage, F. H., Trono, D., & Verma, I. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11382 · Cited by 1,499 · cited 1×
“They have proven to be effective tools for gene delivery to the central nervous system (CNS), generating long-term gene expression in the absence of inflammatio”
BackgroundViral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics
Kay, M. A., Glorioso, J. C., & Naldini, L. (2001) · Nature Medicine · doi:10.1038/83324 · Cited by 1,342
Self-citationKordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.-Y., Palfi, S., Roitberg, B. Z., et al. (2000) · Science · doi:10.1126/science.290.5492.767 · Cited by 1,251 · cited 1×
“gov/htbin-post/Omim/dispmim?168600">Parkinson disease”
Cited by
Items 801–900 of 1,002
Lo, W., Chien, Y., Chiou, G., Tseng, L., Hsu, H., Chang, Y.-L., Lu, K., Chien, C., Wang, M., Chen, Y., et al. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.01.016 · Cited by 42
“Non-viral vectors, such as liposomes, polymers, and peptides, have been reported to be less immunogenic and potentially safer than viral vectors, but so far, their inefficiency in delivering genes is a major problem [22].”
BackgroundMethodNewland, B., Abu-Rub, M., Naughton, M., Zheng, Y., Pinoncely, A. V., Collin, E. C., Dowd, E., Wang, W., & Pandit, A. S. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn4000023 · Cited by 42
Cellular gene transfer mediated by influenza virosomes with encapsulated plasmid DNA
de Jonge, J., Leenhouts, J. M., Holtrop, M. E., Schoen, P., Scherrer, P., Cullis, P. R., Wilschut, J., & Huckriede, A. L. W. (2007) · Biochemical Journal · doi:10.1042/bj20061756 · Cited by 42
Inner ear symptoms and disease: Pathophysiological understanding and therapeutic options
Ciuman, R. R. (2013) · Medical Science Monitor · doi:10.12659/msm.889815 · Cited by 42
“The use of viral vectors is associated with higher transfection efficiency, but there are toxicity and safety problems, such as immunogenicity and insertional mutagenesis [163,164].”
BackgroundZhang, C., Wu, F., Hu, P., & Chen, Z. (2014) · The Journal of Physical Chemistry C · doi:10.1021/jp502383u · Cited by 42
Yuan, S., Ma, T., Zhang, Y., Wang, N., Baloch, Z., & Ma, K. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02159-9 · Cited by 42
“The three major types of viral vectors include retroviruses (RVs), lentiviruses (LVs), and adenoviruses (ADVs) [120].”
BackgroundPorello, I., Bono, N., Candiani, G., & Cellesi, F. (2024) · Polymer Chemistry · doi:10.1039/d4py00234b · Cited by 42
Browne, S., Fontana, G., Rodriguez, B. J., & Pandit, A. S. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300231d · Cited by 41
Progress in the application of exosomes as therapeutic vectors in tumor-targeted therapy
Xie, X., Wu, H., Li, M., Chen, X., Xiao-yun, X., Ni, W., Lu, C., Ni, R., Bao, B., & Xiao, M. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.01.001 · Cited by 41
Emerging Biomedical Applications of Algal Polysaccharides
Rahmati, M., Alipanahi, Z., & Mozafari, M. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190423160357 · Cited by 41
The Benefits of Going Small: Nanostructures for Mammalian Cell Transfection
Tay, A. K. P. (2020) · ACS Nano · doi:10.1021/acsnano.0c04624 · Cited by 41
Peptides as a Material Platform for Gene Delivery: Emerging Concepts and Converging Technologies
Urello, M. A., Hsu, W., & Christie, R. J. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.09.027 · Cited by 42
Zhang, Y., Gao, S., Liang, K., Wu, Z., Yan, X., Liu, W., Li, J., Wu, B., & Du, Y. (2021) · Science Advances · doi:10.1126/sciadv.abi4379 · Cited by 41
Histidine‐enhanced gene delivery systems: The state of the art
Hooshmand, S. E., Sabet, M. J., Hasanzadeh, A., Mousavi, S. M. K., Moghaddam, N. H., Hooshmand, S. A., Rabiee, N., Liu, Y., Hamblin, M. R., & Karimi, M. (2022) · The Journal of Gene Medicine · doi:10.1002/jgm.3415 · Cited by 41
“It should be noted that the most successful approach and the nearest to clinical approval comprises the use of viral vectors.(10)”
BackgroundLi, X., Ma, Y., Yu, X., Zhang, X., Lv, L., Quan, Q., Chen, Y., Yu, G., Liang, Z., Zhang, X., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c07852 · Cited by 41
Lu, J., Atochina‐Vasserman, E. N., Maurya, D. S., Shalihin, M. I., Zhang, D., Chenna, S. S., Adamson, J., Liu, M., Shah, H. U. R., Shah, H., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15061572 · Cited by 41
Saadh, M. J., Baher, H., Li, Y., Chaitanya, M., Arias‐Gonzáles, J. L., Allela, O. Q. B., Mahdi, M. H., Cotrina-Aliaga, J. C., Natrayan, L., Ahjel, S. W., et al. (2023) · Environmental Research · doi:10.1016/j.envres.2023.116490 · Cited by 41
Xu, X., Jiang, Q., Zhang, X., Nie, Y., Zhang, Z., Li, Y., Cheng, G., & Gu, Z. (2015) · Journal of Materials Chemistry B · doi:10.1039/c5tb01070e · Cited by 41
Oligoproline-derived nanocarrier for dual stimuli-responsive gene delivery
Gupta, M. K., Lee, S. H., Crowder, S. W., Wang, X., Hofmeister, L. H., Nelson, C. E., Bellan, L. M., Duvall, C. L., & Sung, H. (2015) · Journal of Materials Chemistry B · doi:10.1039/c5tb00988j · Cited by 41
Targeted gene repair activates Chk1 and Chk2 and stalls replication in corrected cells
Ferrara, L., & Kmiec, E. B. (2006) · DNA repair · doi:10.1016/j.dnarep.2005.11.009 · Cited by 41
Eto, Y., Yoshioka, Y., Ishida, T., Yao, X., Morishige, T., Narimatsu, S., Mizuguchi, H., Mukai, Y., Okada, N., Kiwada, H., et al. (2010) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.33.1540 · Cited by 41
Therapeutic angiogenesis using genetically engineered human endothelial cells
Cho, S., Yang, F., Son, S. M., Park, H., Green, J. J., Bogatyrev, S. R., Mei, Y., Park, S., Langer, R., & Anderson, D. G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.006 · Cited by 41
“Viral gene delivery is also plagued by production/manufacturing challenges and other limitations including nucleic acid cargo capacity [12].”
InfluentialLiu, X.-Y., Ho, W., Hung, W. J., & Shau, M. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.08.052 · Cited by 41
Deng, Q., Li, X., Zhu, L., He, H., Chen, D., Chen, Y., & Yin, L. (2017) · Biomaterials Science · doi:10.1039/c7bm00334j · Cited by 41
Miao, J., Yang, X., Gao, Z., Li, Q., Meng, T., Wu, J., Yuan, H., & Hu, F. (2019) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2019.02.047 · Cited by 41
Brito, L., Little, S. R., Langer, R., & Amiji, M. M. (2008) · Biomacromolecules · doi:10.1021/bm7011373 · Cited by 41
Gene Therapy for Genetic Syndromes: Understanding the Current State to Guide Future Care
Henderson, M. L., Zieba, J. K., Li, X., Campbell, D. B., Williams, M. R., Vogt, D. L., Bupp, C. P., Edgerly, Y. M., Rajasekaran, S., Hartog, N., et al. (2024) · BioTech · doi:10.3390/biotech13010001 · Cited by 41
Jeong, E. J., Choi, M., Lee, J., Rhim, T., & Lee, K. Y. (2015) · Nanoscale · doi:10.1039/c5nr06903c · Cited by 40
microRNA: A Promising Diagnostic Biomarker and Therapeutic Target for Hepatocellular Carcinoma
Li, X., Yang, W., Lou, L., Chen, Y., Wu, S., & Ding, G. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-013-3006-1 · Cited by 40
Oligonucleotide optical switches for intracellular sensing
Giannetti, A. E., Tombelli, S., & Baldini, F. (2013) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-013-7086-8 · Cited by 40
“The advantages of such nanoparticle-based probes with respect to conventional approaches derive mainly from their relatively low toxicity when compared with earlyused viral vectors [73] and from their ease of processing and resistance to degradation, which can be also enhanced by proper functionalization.”
BackgroundSkandrani, N., Barras, A., Legrand, D., Gharbi, T., Boulahdour, H., & Boukherroub, R. (2014) · Nanoscale · doi:10.1039/c4nr01110d · Cited by 40
Polymeric nanoparticle‐based delivery of TRAIL DNA for cancer‐specific killing
Tzeng, S. Y., Wilson, D. R., Hansen, S. K., Quiñones‐Hinojosa, A., & Green, J. J. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10019 · Cited by 40
“mutagenesis, and limitations to the size of the cargo that they can carry have limited their translation to the clinic.(9,10) The field of nanomedicine has recently produced many non-viral gene delivery agents based on biomaterials that are capable of facilitating intracellular delivery of DNA and can be engineered fo…”
BackgroundSimple Derivation of Spinal Motor Neurons from ESCs/iPSCs Using Sendai Virus Vectors
Goto, K., Imamura, K., Komatsu, K., Mitani, K., Aiba, K., Nakatsuji, N., Inoue, M., Kawata, A., Yamashita, H., Takahashi, R., et al. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2016.12.007 · Cited by 40
Rissanou, A. N., Ouranidis, A., & Karatasos, K. (2020) · Soft Matter · doi:10.1039/d0sm00736f · Cited by 41
Rational nanocarrier design towards clinical translation of cancer nanotherapy
Guo, D., Ji, X., & Luo, J. (2021) · Biomedical Materials · doi:10.1088/1748-605x/abe35a · Cited by 40
The Role of Rds in Outer Segment Morphogenesis and Human Retinal Disease
Farjo, R. A., & Naash, M. I. (2006) · Ophthalmic Genetics · doi:10.1080/13816810600976806 · Cited by 40
Shimanovich, U., Tkacz, I. D., Eliaz, D., Cavaco-Paulo, A. M., Michaeli, S., & Gedanken, A. (2011) · Advanced Functional Materials · doi:10.1002/adfm.201100963 · Cited by 40
Oligonucleotide delivery by chitosan-functionalized porous silicon nanoparticles
Kafshgari, M. H., Delalat, B., Tong, W. Y., Harding, F. J., Kaasalainen, M. H., Salonen, J., & Voelcker, N. H. (2015) · Nano Research · doi:10.1007/s12274-015-0715-0 · Cited by 40
“demonstrated in vivo, however, human clinical trials of gene therapies have been not satisfactory except a couple of individual cases of success against a background of unexpectedly high morbidity and mortality rates [7-10].”
BackgroundGrasso, G., Deriu, M. A., Patrulea, V., Borchard, G., Möller, M., & Danani, A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186816 · Cited by 40
Therapeutic Potency of Nanoformulations of siRNAs and shRNAs in Animal Models of Cancers
Karim, M. E., Tha, K. K., Othman, I., Uddin, M. B., & Chowdhury, E. H. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10020065 · Cited by 40
“The engineered viral vectors possess high specificity, unassisted entry to the cell membrane, lack of replication and pathogenicity and higher gene expression efficiency [40,41].”
BackgroundPerspectives in vector development for systemic cancer gene therapy.
Hatefi, A., & Canine, B. (2009) · PubMed · Cited by 40
Viral Vectors for Cancer Gene Therapy: Viral Dissemination and Tumor Targeting
Jia, W. W.-G., & Zhou, Q. Y. (2005) · Current Gene Therapy · doi:10.2174/1566523052997460 · Cited by 40
RGD Conjugation to Polyethyleneimine Does Not Improve DNA Delivery to Bone Marrow Stromal Cells
Clements, B. A., Bai, J. H., Kucharski, C., Farrell, L.-L., Lavasanifar, A., Ritchie, B. C., Ghahary, A., & Uludağ, H. (2006) · Biomacromolecules · doi:10.1021/bm060073w · Cited by 40
Stevens, J. (2003) · Journal of Health Politics Policy and Law · doi:10.1215/03616878-28-6-1033 · Cited by 40
Antibacterial activity of silver and gold nanoparticles that have been synthesized by curcumin
Amini, S. M., & Shahroodian, S. (2024) · Inorganic and Nano-Metal Chemistry · doi:10.1080/24701556.2024.2352352 · Cited by 39
Artificial intelligence-powered nanomedicine
Luo, G., 蒋显超, Hu, C., Li, L., Yan, L., Xiao, G., Duo, Y., & Zhang, X. (2026) · Chemical Society Reviews · doi:10.1039/d5cs01406a · Cited by 40
Godinho, B. M. D. C., McCarthy, D. J., Torres‐Fuentes, C., Beltrán, C. J., McCarthy, J., Quinlan, A., Ogier, J. R., Darcy, R., O’Driscoll, C. M., & Cryan, J. F. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.09.068 · Cited by 39
“Despite their ability to transduce a wide range of cell types, several concerns have been raised against viral vectors regarding their immunogenicity and safety (Thomas et al., 2003).”
BackgroundPrecise targeted integration by a chimaeric transposase zinc-finger fusion protein
Feng, X., Bednarz, A. L., & Colloms, S. D. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp1068 · Cited by 39
“Retroviral vectors have been used extensively to integrate DNA in gene therapy trials (28).”
BackgroundWang, L., Wu, T. H., Wu, D., & You, Y. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b04327 · Cited by 39
Recent advances in developing specific therapies for haemophilia
Ling, G., Nathwani, A. C., & Tuddenham, E. G. D. (2018) · British Journal of Haematology · doi:10.1111/bjh.15084 · Cited by 40
“…successfully treated the condition, but the use of an oncoretroviral vector inevitably led to insertion of the transgene into the host genome, which in a tiny proportion of insertions upstream of the LMO2 gene in some recipients caused a leukaemia like syndrome (Thomas et al, 2003).”
BackgroundAlsaggar, M., & Liu, D. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1437919 · Cited by 39
“Whereas viral systems facilitate nuclear delivery of nucleic acids-based drugs through their natural infection pathway [178], non-viral carriers rely mostly on endogenous nuclear transport events and intrinsic features of the nuclear membrane.”
BackgroundScaffold-Mediated Gene Delivery for Osteochondral Repair
Madry, H., Venkatesan, J. K., Carballo-Pedrares, N., Rey‐Rico, A., & Cucchiarini, M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12100930 · Cited by 39
“Nonviral vectors are generally considered safe carriers compared with viral constructs as they do not carry the risk of insertional mutagenesis (nonviral vectors are kept under episomal forms) and have a low immunogenicity (nonviral vectors have no intrinsic viral coding sequences) [40].”
BackgroundCerrato, C. P., Kivijärvi, T., Tozzi, R., Lehto, T., Gestin, M., & Langel, Ü. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb01106a · Cited by 39
Protective Effect of Edaravone against Cationic Lipid-Mediated Oxidative Stress and Apoptosis
Terada, T., Kulkarni, J. A., Huynh, A., Tam, Y. Y. C., & Cullis, P. R. (2020) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b20-00679 · Cited by 39
Kinoshita, Y., Mohamed, F. F., de Oliveira, F. A., Narisawa, S., Miyake, K., Foster, B. L., & Millán, J. L. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4382 · Cited by 39
“Finally, vector-host interactions such as immunemediated responses and the emergence of neutralizing antibodies (NAb) against the virus capsid and/or transgene product are known as the major challenges that virus-vector-mediated gene therapy has to overcome before its clinical application.((74-76)) We did not perform…”
BackgroundKim, H., Song, B., Park, S., Choi, S. W., Moon, H., Hwang, K., Kang, S., Moon, S., Yang, Y., Kwon, I. C., et al. (2022) · Science Advances · doi:10.1126/sciadv.abj6621 · Cited by 39
“Despite inherently high transfection efficiencies of viral methods such as transgene activation, associated safety concerns relating to residual expression and insertion-mutagenesis impose severe limitations on their clinical applications ( 5 ).”
Vimentin Knockdown Decreases Corneal Opacity
Das, S. K., Gupta, I., Cho, Y. K., Zhang, X., Uehara, H., Muddana, S. K., Bernhisel, A. A., Archer, B. J., & Ambati, B. K. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-13494 · Cited by 39
Song, Y., Lou, B., Zhao, P., & Lin, C. (2014) · Molecular Pharmaceutics · doi:10.1021/mp4006672 · Cited by 39
Dhaliwal, A., Maldonado, M., Han, Z., & Segura, T. (2010) · Acta Biomaterialia · doi:10.1016/j.actbio.2010.03.038 · Cited by 39
“Although viral delivery is generally more efficient than non-viral approaches, it has limitations due to its potential immunogenicity and insertion mutagenesis [1].”
BackgroundSoto‐Sánchez, C., Martínez, G., Humphreys, L., Puras, G., Sesma, J. Z., Pedraz, J. L., & Fernández, E. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.01.012 · Cited by 39
Incani, V., Lin, X., Lavasanifar, A., & Uludağ, H. (2009) · ACS Applied Materials & Interfaces · doi:10.1021/am8002445 · Cited by 39
Non-Viral Nucleic Acid Delivery Strategies to the Central Nervous System
Tan, J.-K. Y., Sellers, D., Pham, B., Pun, S., & Horner, P. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00108 · Cited by 26
“…viral vectors are still the main type of vehicles used in clinical trials, non-viral vectors are gaining traction due to their potential safety advantages, greater customization, ease of manufacturing and ability to deliver all nucleic acid varieties (Niidome and Huang, 2002; Thomas et al., 2003).”
BackgroundDual peptide-mediated targeted delivery of bioactive siRNAs to oral cancer cells in vivo
Alexander-Bryant, A. A., Zhang, H., Attaway, C. C., Pugh, W., Eggart, L., Sansevere, R. M., Andino, L. M., Dinh, L., Cantini, L. P., & Jakymiw, A. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.07.004 · Cited by 39
Lentivirus-mediated gene transfer to the rat, ovine and human cornea
Parker, D. G., Kaufmann, C., Brereton, H. M., Anson, D. S., Francis-Staite, L., Jessup, C. F., Marshall, K., Tan, C., Koldej, R. M., Coster, D. J., et al. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302921 · Cited by 39
Treatment of peripheral sensorineural hearing loss: gene therapy
Duan, M., Venail, F., Spencer, N. J., & Mezzina, M. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302369 · Cited by 40
Transgenic livestock made easy
Whitelaw, B. (2004) · Trends in biotechnology · doi:10.1016/j.tibtech.2004.02.005 · Cited by 39
Introduction of impermeable actin-staining molecules to mammalian cells by optoporation
Dhakal, K. R., Black, B., & Mohanty, S. K. (2014) · Scientific Reports · doi:10.1038/srep06553 · Cited by 38
Non-viral nucleic acid containing nanoparticles as cancer therapeutics
Kozielski, K., Rui, Y., & Green, J. J. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1190707 · Cited by 38
Combining Gene and Stem Cell Therapy for Peripheral Nerve Tissue Engineering
Busuttil, F., Rahim, A. A., & Phillips, J. B. (2016) · Stem Cells and Development · doi:10.1089/scd.2016.0188 · Cited by 38
“Ideal characteristics of a viral vector include the abilities to be reproducibly and stably produced and purified to high titers, to mediate targeted delivery and transgene expression without inducing harmful side effects [56].”
Priyam, A., Nagar, P., Sharma, A. K., & Kumar, P. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.10.063 · Cited by 38
Nanoparticle-mediated gene therapy strategies for mitigating inflammatory bowel disease
Verma, P., Srivastava, A., Srikanth, C. V., & Bajaj, A. (2020) · Biomaterials Science · doi:10.1039/d0bm01359e · Cited by 38
Nonviral gene delivery systems: From simple transfection agents to artificial viruses
Mastrobattista, E., Bravo, S. A., van der Aa, M. A. E. M., & Crommelin, D. J. A. (2005) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2005.04.002 · Cited by 38
“However, recently reported safety issues have set back a fast development of this type of DNA carriers [ 1 ,2].”
Wang, Y., Li, J., & Oupický, D. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1440-1 · Cited by 38
Treating colon cancer with a suicide gene delivered by self-assembled cationic MPEG–PCL micelles
Duan, X., Wang, P., Men, K., Gao, X., Huang, M., Gou, M., Chen, L., Qian, Z., & Wei, Y. (2012) · Nanoscale · doi:10.1039/c2nr30079f · Cited by 38
Rajpal, Mann, A., Khanduri, R., Naik, R. J., & Ganguli, M. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.081 · Cited by 38
Cytoplasmic RNA viruses as potential vehicles for the delivery of therapeutic small RNAs
Usme-Ciro, J. A., Campillo-Pedroza, N., Almazán, F., & Gallego-Gómez, J. C. (2013) · Virology Journal · doi:10.1186/1743-422x-10-185 · Cited by 39
“Each viral vector has specific advantages, limitations, and range of applications [24].”
BackgroundDuan, L., Yan, Y., Liu, J., Wang, B., Li, P., Hu, Q., & Chen, W. (2016) · Scientific Reports · doi:10.1038/srep24867 · Cited by 38
Yu, X., Hu, L., He, H. Z., Zhang, F., Wang, M., Wei, W., & Xia, Z. (2019) · Analytica Chimica Acta · doi:10.1016/j.aca.2018.12.062 · Cited by 38
Magnetically enhanced adeno-associated viral vector delivery for human neural stem cell infection
Kim, E., Oh, J. S., Ahn, I., Park, K. I., & Jang, J. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.07.075 · Cited by 38
“Adenovirus-mediated vectors have demonstrated efficient gene delivery and transient gene expression in stem cells, but virally encoded factors that can cause immune responses may hinder the widespread use of adenoviral vectors for stem cell applications [10,11].”
BackgroundGrabowska, A. K., Lipińska, A. D., Rohde, J., Szewczyk, B., Bieńkowska-Szewczyk, K., & Rziha, H.-J. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.03.067 · Cited by 38
“However, potential disadvantages f some of these vectors consist in their cytotoxicity, in vaccine irus multiplication in the immunized host, and in pre-existing r induced immunity against the vector virus diminishing or preenting efficient immunity against foreign antigens [3,10].”
BackgroundSuccesses and risks of gene therapy in primary immunodeficiencies
Chinen, J., & Puck, J. M. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.01.765 · Cited by 38
Gene therapy for hemophilia: past, present and future
George, L. A., & Fogarty, P. F. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.10.002 · Cited by 37
Shau, M. D., Shih, M. F., Lin, C.-C., Chuang, I.-C., Hung, W. C., Hennink, W. E., & Cherng, J. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.04.006 · Cited by 37
Zhu, Y., Liang, G., Sun, B., Tian, T., Hu, F. H., & Xiao, Z. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s84927 · Cited by 37
“8 In contrast, non-viral delivery vectors have emerged as an alternative strategy for gene delivery in the context of avoiding the defects of the viral vectors.”
Transcutaneous delivery of DNA/mRNA for cancer therapeutic vaccination
Sun, X., Zeng, L., & Huang, Y. (2019) · The Journal of Gene Medicine · doi:10.1002/jgm.3089 · Cited by 37
“ing the biological methods, viral vectors are very efficient for delivering exogenous genes into host cells and exploiting the cellular machinery to facilitate the replication.(28) For example, adenovirus(29) and poxvirus(30) based vaccines encoding human carcinoembryonic antigen (CEA) and epitope ovalbumin (OVA)257–2…”
MethodMukherjee, M. B., Mullick, R., Reddy, B. U., Das, S., & Raichur, A. M. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00814 · Cited by 37
In vivo gene immunotherapy for cancer
Mai, D. H., June, C. H., & Sheppard, N. C. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo3603 · Cited by 37
Lectin functionalized nanocarriers for gene delivery
Gajbhiye, V., & Gong, S. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.01.005 · Cited by 37
Wei, Z., Huang, Y., Zhao, D., Hu, Z., Li, Z., & Liang, Z. (2015) · Scientific Reports · doi:10.1038/srep07618 · Cited by 37
Mangipudi, S. S., Canine, B., Wang, Y., & Hatefi, A. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800251x · Cited by 37
Rallapalli, P. M., Orengo, C. A., Studer, R. A., & Perkins, S. J. (2014) · Molecular Biology and Evolution · doi:10.1093/molbev/msu248 · Cited by 38
“A major problem faced in FIX gene therapy is the low level of protein expression, in part due to a different codon usage in the organism that produces the protein (Thomas et al. 2003).”
Cheng, W., Yang, C. H., Hedrick, J. L., Williams, D. F., Yang, Y. Y., & Ashton‐Rickardt, P. G. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.01.090 · Cited by 37
Elucidating the role of free polycations in gene knockdown by siRNA polyplexes
Klauber, T. C. B., Søndergaard, R. V., Sawant, R. R., Torchilin, V. P., & Andresen, T. L. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.02.021 · Cited by 37
Cationic and hydrolysable branched polymers by RAFT for complexation and controlled release of dsRNA
Cook, A. B., Peltier, R., Hartlieb, M., Whitfield, R., Moriceau, G., Burns, J. A., Haddleton, D. M., & Perrier, S. (2018) · Polymer Chemistry · doi:10.1039/c8py00804c · Cited by 37
Gargouri, M., Sapin‐Minet, A., Bouali, S., Bécuwe, P., Merlin, J. L., & Maincent, P. (2009) · Technology in Cancer Research & Treatment · doi:10.1177/153303460900800605 · Cited by 37
Synthetic Biology—Toward Therapeutic Solutions
Haellman, V., & Fussenegger, M. (2015) · Journal of Molecular Biology · doi:10.1016/j.jmb.2015.08.020 · Cited by 36
Lin, P., Gao, Y., Xue, Y., Huang, S., & Zhuo, R. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.02.031 · Cited by 36
“The safety problem of virus as highly potent gene delivery vector, including severe immunological, toxicological responses and random integration into host genome, has limited its application [2].”
BackgroundYu, B., Ouyang, C., Qiu, K., Zhao, J., Ji, L., & Chao, H. (2015) · Chemistry - A European Journal · doi:10.1002/chem.201405151 · Cited by 36
Kramerov, A. A., Saghizadeh, M., & Ljubimov, A. V. (2016) · Journal of Visualized Experiments · doi:10.3791/54058-v · Cited by 36
Majzoub, R. N., Wonder, E. A., Ewert, K. K., Kotamraju, V. R., Teesalu, T., & Safinya, C. R. (2016) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.6b04441 · Cited by 36
Metadata
- Authors
- Thomas, C. E., Ehrhardt, A., & Kay, M. A.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- Kay, Mark A.
- Venue
- Nature Reviews Genetics
- Published
- 2003-05-01
- Volume
- 4
- Issue
- 5
- Pages
- 346-358
- ISSN
- 1471-0056 (ISSN-L)
- 1471-0064
- OpenAlex
- W2014356856
- Cited by
- 2,501
- References
- 124
- Citations by year
- 2026: 41 · 2025: 59 · 2024: 110 · 2023: 98 · 2022: 109 · 2021: 116 · 2020: 151 · 2019: 153 · 2018: 150 · 2017: 168 · 2016: 142 · 2015: 143 · 2014: 148 · 2013: 122 · 2012: 109
- FWCI
- 8.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Pennsylvania
- Hospital for Sick Children
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- gene therapy, viral vectors, clinical gene therapy, gene therapy safety, retroviral vectors, clinical trials
- MeSH terms
- Dependovirus, Adenoviridae, Defective Viruses, Genetic Vectors, Humans, Neoplasms, Retroviridae, Viruses, Genetic Therapy, Lentivirus, Simplexvirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.